Short Interest in Caring Brands, Inc. (NASDAQ:CABR) Grows By 278.7%

Caring Brands, Inc. (NASDAQ:CABR) saw a large growth in short interest in May. As of May 29th, there was short interest totaling 20,796 shares, a growth of 278.7% from the May 14th total of 5,492 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average trading volume of 101,232 shares, the short-interest ratio is presently 0.2 days.

Caring Brands Stock Performance

CABR traded down $0.01 during trading on Thursday, reaching $1.10. 26,545 shares of the stock were exchanged, compared to its average volume of 118,874. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.62 and a current ratio of 5.66. The business’s 50 day moving average price is $1.11. Caring Brands has a twelve month low of $0.71 and a twelve month high of $5.35. The company has a market cap of $9.96 million and a PE ratio of -1.71.

Caring Brands (NASDAQ:CABR) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Caring Brands in a research report on Friday, May 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Caring Brands

An institutional investor recently bought a new position in Caring Brands stock. Jane Street Group LLC bought a new stake in shares of Caring Brands, Inc. (NASDAQ:CABR) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned 0.25% of Caring Brands as of its most recent filing with the Securities and Exchange Commission.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.